- Home
- STG vs SPRO Comparison
STG vs SPRO Comparison
Compare STG & SPRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STG
- SPRO
- Stock Information
- Founded
- STG 2003
- SPRO 2013
- Country
- STG China
- SPRO United States
- Employees
- STG N/A
- SPRO N/A
- Industry
- STG Other Consumer Services
- SPRO Biotechnology: Pharmaceutical Preparations
- Sector
- STG Real Estate
- SPRO Health Care
- Exchange
- STG Nasdaq
- SPRO Nasdaq
- Market Cap
- STG 118.9M
- SPRO 121.0M
- IPO Year
- STG 2018
- SPRO 2017
- Fundamental
- Price
- STG $8.82
- SPRO $1.90
- Analyst Decision
- STG
- SPRO Buy
- Analyst Count
- STG 0
- SPRO 4
- Target Price
- STG N/A
- SPRO $5.00
- AVG Volume (30 Days)
- STG 8.6K
- SPRO 398.1K
- Earning Date
- STG 08-14-2025
- SPRO 11-13-2025
- Dividend Yield
- STG N/A
- SPRO N/A
- EPS Growth
- STG N/A
- SPRO N/A
- EPS
- STG 3.59
- SPRO N/A
- Revenue
- STG $279,374,215.00
- SPRO $48,576,000.00
- Revenue This Year
- STG N/A
- SPRO N/A
- Revenue Next Year
- STG N/A
- SPRO N/A
- P/E Ratio
- STG $2.45
- SPRO N/A
- Revenue Growth
- STG N/A
- SPRO N/A
- 52 Week Low
- STG $4.28
- SPRO $0.51
- 52 Week High
- STG $15.00
- SPRO $3.22
- Technical
- Relative Strength Index (RSI)
- STG 46.35
- SPRO 39.50
- Support Level
- STG $8.11
- SPRO $1.91
- Resistance Level
- STG $8.95
- SPRO $2.18
- Average True Range (ATR)
- STG 0.56
- SPRO 0.10
- MACD
- STG -0.10
- SPRO 0.01
- Stochastic Oscillator
- STG 39.42
- SPRO 19.18
About STG Sunlands Technology Group
Sunlands Technology Group is a provider of online post-secondary and professional education services in China. The company offers various degree- and diploma-oriented post-secondary courses through its online platforms. In addition, it provides online professional courses and educational content to help students prepare for professional certification exams and attain professional skills. The Group has one operating segment, which is the provision of online education services.
About SPRO Spero Therapeutics Inc.
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.